$CLX

Clorox Recalls 6.3 Million Bottles of Mistolin and Lestoil Cleaners Over Bacteria Risk to Vulnerable Users

Clorox is recalling 6.3 million bottles of scented Mistolin and Lestoil cleaners in Puerto Rico and the U.S. Virgin Islands due to potential Pseudomonas aeruginosa contamination. The recall affects products with date codes starting 'PR01' and made between April 2025 and June 2026. Vulnerable users, such as those with weakened immune systems or medical devices, are at risk. No injuries have been reported. Clorox offers refunds for affected products.

Original reporting
Published Sep 4, 2026, 12:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Clorox Recalls 6.3 Million Bottles of Mistolin and Lestoil Cleaners Over Bacteria Risk to Vulnerable Users — source image
Decision brief

The 30-second read

$CLXBearishLow
01

Why it matters

The recall could affect consumer confidence and lead to short‑term sales dip, but broader brand remains strong.

02

Market read

Recall is region‑specific with limited immediate financial impact, but signals potential quality control risks for Clorox.

03

What to watch

Potential regulatory follow‑up could increase compliance costs for Clorox's manufacturing processes.

Relevance 6/10Novelty 6/10Timing: Sept 3 2026 recall announcement

Background

Clorox previously recalled Pine‑Sol cleaners in 2022 for the same bacterial issue, indicating possible systemic quality control concerns.

Company-level read

Ticker impact

$CLXBearishMedium confidence
Context

Clorox announced a recall of 6.3 million bottles of Mistolin and Lestoil cleaners due to bacterial contamination risk.

Expected impact

Modest downside pressure pending market reaction to recall news.

Evidence & confidence

Recall size is sizable but limited to Puerto Rico and U.S. Virgin Islands; no injuries reported, so impact likely limited.

Market effects

Consumer‑goods and household‑cleaner sector may see heightened scrutiny on product safety.

Puerto Rico and U.S. Virgin Islands retailers could see short‑term inventory adjustments.

Limited, as recall is region‑specific and does not affect global supply.

Counterpoint

Recall may be overblown; limited geography and no injuries could keep stock stable.

Key entities

  • Clorox Manufacturing Company of Puerto Rico, Inc.

    Manufacturer of the recalled cleaning products.

  • Consumer Product Safety Commission (CPSC)

    Issued the recall notice.

Related articles

$CLXMedAI 8/10

Clorox stock hits 52-week low at 84.69 USD

Clorox (CLX) stock hit a 52-week low of $84.74, down 31.51% over the past year. Despite this, InvestingPro suggests it's undervalued with a 5.89% dividend yield. Q4 earnings per share were $1.66, missing estimates. UBS raised its price target to $105, maintaining a Neutral rating. Goldman Sachs and Morgan Stanley reported on broader consumer staples trends.

$CLXMed

Can Cost Savings Offset Inflation & Protect Clorox's Margins?

Clorox (CLX) reported a 520 basis point gross margin contraction in Q4 fiscal 2026 due to inflation and mix challenges. The company is focusing on cost savings and productivity initiatives to offset inflationary pressures, but expects margins to remain pressured in fiscal 2027. CLX shares have risen 5.2% in the past three months, with a forward P/E of 15.97X.

$CLXMedAI 8/10

How GOJO Could Shape Clorox's Fiscal 2027 Growth and Margin Outlook

Clorox (CLX) expects fiscal 2027 net sales to rise 13-14%, with GOJO contributing 9.5 points. Q1 sales projected at 31-32%, including 15 points from GOJO. Adjusted earnings forecasted at $5.70-$6.00 per share, up 3-8%. Gross margin expected at 42%, with pressure from GOJO inventory costs and inflation. Integration costs and inflation pose near-term challenges.

$CLXMedAI 8/10

Is Clorox Stock Worth Buying as GOJO Growth Meets Margin Pressure?

Clorox (CLX) reports Q4 net sales of $1.95B, up 2% YoY, with GOJO contributing 10 percentage points. Fiscal 2027 sales expected to rise 13-14%, with adjusted EPS at $5.70-$6.00. Gross margins declined due to inflation and higher costs. Organic sales growth is muted, with ERP comparisons aiding growth. CLX trades at 17.9X forward earnings, below its sub-industry multiple.

$CLXMed

Are Wall Street Analysts Predicting Clorox Stock Will Climb or Sink?

The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.

$CLXMedAI 8/10

Clorox (CLX) Q4 2026 Earnings Call Transcript

Clorox (CLX) reported Q4 FY2026 net sales of $1.95B, down 2% (GOJO added about 10 points). Organic sales fell 13% and adjusted EPS was $1.66, down 42%. Gross margin was 41.3%. For FY2027, it guided organic sales growth of 3.5% to 4.5% and adjusted EPS of $5.70 to $6.00, citing inflation headwinds of $200M+.